Press "Enter" to skip to content

Dow Jones Newswires: Novartis hemoglobinuria trial meets two primary endpoints

http://www.marketwatch.com/news/story.asp?guid=%7B20C0C4D5-7425-4434-F126-412FE874EE3A%7D&siteid=rss&rss=1
The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia…

More from BusinessMore posts in Business »
More from UncategorizedMore posts in Uncategorized »